The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InING Groep NV significantly reduced its holding in Thermo Fisher Scientific Inc. (TMO) by 80.0% during the third quarter. This reduction brings ING's current stake in the life sciences company to an estimated $15.53 million. The move comes as Thermo Fisher Scientific announced a substantial $5.00 billion stock buyback program, signaling management's confidence in the company's valuation. Despite ING's divestment, financial analysts generally maintain a 'Moderate Buy' rating for TMO shares. The average target price for TMO stands at $633.68, reflecting a positive outlook from the analytical community. This juxtaposition of institutional selling and a robust buyback initiative creates a mixed sentiment around TMO's near-term performance.